BioPharma Resources

Drug Trial Radar · NCT05422222

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Jun 21, 2022

Primary completion

Jun 30, 2030

Study completion Jun 30, 2030

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Jun 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Conditions

  • Cystic Fibrosis

Interventions

  • VX-121/TEZ/D-IVADrug

    Fixed-dose combination for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Observed Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ, D-IVA, and Relevant MetabolitesTime frame: From Day 1 up to Day 22
  2. Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to Day 50
  3. Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to Week 28

Locations

38 sites in 10 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Orange County

    Orange, California

  • Stanford University Clinical and Translational Research Unit

    Palo Alto, California

  • Children's Hospital of Colorado

    Aurora, Colorado

  • The Emory Clinic / Children's Healthcare of Atlanta at Egleston

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Riley Hospital for Children at Indiana University Health

    Indianapolis, Indiana

  • Boston Children's Hospital

    Boston, Massachusetts

  • Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota

    Minneapolis, Minnesota

  • The Children's Mercy Hospital

    Kansas City, Missouri

  • Washington University School of Medicine / St. Louis Children's Hospital

    St Louis, Missouri

  • Cohen Children's Medical Center

    Lake Success, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Texas Children's Hospital - Wallace Tower

    Houston, Texas

  • Vermont Lung Center

    Colchester, Vermont

  • American Family Childrens Hospital

    Madison, Wisconsin

  • The Kids Research Institute Australia

    Nedlands, Australia

  • Women's and Children's Hospital

    North Adelaide, Australia

  • The Royal Children's Hospital

    Parkville, Australia

  • Queensland Children's Hospital

    South Brisbane, Australia

  • The Hospital for Sick Children

    Toronto, Canada

  • British Columbia Children's Hospital

    Vancouver, Canada

  • CHU Lyon - Hopital Femme Mere-Enfant

    Bron, France

  • Hopital Necker, Enfants Malades

    Paris, France

  • Charité - Paediatric Pulmonology Department

    Berlin, Germany

  • Universitatsklinikum Essen

    Essen, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Erasmus Medical Center / Sophia Children's Hospital

    Rotterdam, Netherlands

  • Starship Children's Hospital

    Grafton, New Zealand

  • Sahlgrenska Universitetssjukhuset

    Gothenburg, Sweden

  • Karolinska University Hospital - Pulmonology

    Stockholm, Sweden

  • Inselspital - Universitaetsspital Bern

    Bern, Switzerland

  • Kinderspital Zurich

    Zurich, Switzerland

  • Children and Young Adults Research Unit

    Cardiff, United Kingdom

  • Great Ormond Street Hospital for Children

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.